Open AccessAztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Enterobacterales in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020
Author(s) -
Amelia Bhatnagar,
Sandra Boyd,
Sarah Sabour,
Janine Bodnar,
Elizabeth Nazarian,
Nadine Peinovich,
Wagner Christine,
Bradley Craft,
Paula Snippes Vag,
Justin Simpson,
Victoria Stone,
Michelle C. S. Therrien,
Allen C. Bateman,
Danielle Lower,
J. Huang,
Stephanie Gumbis,
David Lonsway,
Joseph D. Lutgring,
Maria Karlsson,
Allison C Brown
Publication year - 2021
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00486-21
Subject(s) - aztreonam , ceftazidime/avibactam , avibactam , medicine , antibiotics , broth microdilution , microbiology and biotechnology , ceftazidime , antibiotic resistance , biology , minimum inhibitory concentration , bacteria , pseudomonas aeruginosa , genetics , imipenem
Aztreonam-avibactam is a drug combination pending phase 3 clinical trials and is suggested for treatment of severe infections caused by metallo-beta-lactamase (MBL)-producingEnterobacterales by combining ceftazidime-avibactam and aztreonam. Beginning in 2019, four Antibiotic Resistance Laboratory Network regional laboratories offered aztreonam-avibactam susceptibility testing by broth microdilution.